Effective reduction in blood pressure (BP) improves survival and morbidity in hypertensive patients. Combination therapy with multiple antihypertensive agents is frequently required in clinical practice and therapeutic trials to achieve target BP. Patients at elevated cardiovascular risk achieve the greatest benefit from equivalent reduction in BP and also require more stringent BP control. In patients with hypertension and diabetes mellitus or renal disease, BP control is of primary importance and blockade of the renin-angiotensin system (RAS) should be the initial therapeutic intervention. Choice of combination therapy has been insufficiently studied in major clinical cardiovascular endpoint trials. Diuretic therapy remains the logical addition to RAS blockade. Despite previous debate, the available evidence suggests long-acting calcium-channel blockers are also a safe and very effective addition to improve BP control further. The choice of antihypertensive combination therapy should not override the fundamental necessity of lowering BP to target levels.
Introduction
The patient at elevated cardiovascular risk will receive maximum benefit through 'tight' blood pressure (BP) control and this is reflected in current advisory guidelines, which are summarised in Table 1 . [1] [2] [3] [4] [5] [6] [7] Whilst there is a degree of disparity in the absolute target values for antihypertensive treatment, it is clear that the patient should be stratified according to whether primary or secondary prophylaxis is required, as well as according to the level of cardiovascular risk, comorbidity and evidence of target organ damage. Major clinical cardiovascular risk factors to be considered include hypertension, diabetes mellitus/ impaired glucose tolerance (IGT), prior cardiovascular events, renal disease, dyslipidaemia, smoking, obesity, alcohol, physical inactivity, age >60 years, male/post-menopausal female, positive family history, ethnicity and socio-economic status. Clinical examination and investigations of target organ damage should be directed towards detection of left ventricular hypertrophy (LVH), ischaemic heart disease (IHD), heart failure, stroke/TIA, nephropathy, peripheral vascular disease or retinopathy. It has been noted that subjects with diabetes mellitus and those with renal disease and hypertension experience greater benefit from equivalent antihypertensive treatment, in terms of microvascular, macrovascular and mortality outcome, than the hypertensive population in general because of their significantly elevated risk profile. Results from the UK Prospective Diabetes Study (UKPDS) 8 and the diabetic cohort of the stepped-care BP orientated Hypertension Optimal Treatment (HOT) 9 trial demonstrated that aggressively lowering diastolic BP (DBP) to <85 and <80 mmHg, in the presence of diabetes, reduced the incidence of macrovascular complications by about one-third and one-half, respectively. In UKPDS, the benefit was greater than that achieved through tight glycaemic control and it is likely that these benefits are additive.
Review
The benefits of BP lowering in diabetes have been reinforced by substudies of the placebo-controlled hypertension trials, Systolic Hypertension in Europe (Syst-Eur) 10 and Systolic Hypertension in the Elderly Program (SHEP). 11 Similarly, in subjects with proteinuric renal disease, the Modification of Diet in Renal Disease (MDRD) Study showed that reducing BP to a mean arterial pressure of 92 mmHg slowed the progression of renal disease to a greater extent than a mean arterial pressure of 107 mmHg, 12 with the benefits being greatest in patients with proteinuria of >1 g/day. The additional benefit in more severe renal disease can be extrapolated to both diabetic 13 and non-diabetic nephropathy. 14 MDRD achieved tighter BP control than more recent randomised trials of angiotensinconverting enzyme (ACE) inhibition on progression of renal disease, 14, 15 and so the absolute level of target BP remains uncertain.This data has established the fundamental clinical importance of BP lowering in the hypertensive patient with diabetes and/or renal disease.
To achieve these aggressive BP targets, multiple antihypertensive medications are usually required. In the presence of diabetes and renal disease, the first-line agent of choice is an ACE inhibitor (ACE-I) or an angiotensin II (Ang II) AT 1receptor blocker (ARB). This article reviews the current clinical evidence assessing the need for additional pharmacological agents focussing upon combination antihypertensive therapy with reninangiotensin system (RAS) blockade and calcium channel blockers (CCBs) in patients at high cardiovascular risk; (i) those with hypertension and diabetes and (ii) those with renal disease and hypertension.
The need for combination therapy
Achieving target BP goals frequently requires combination therapy with two or more antihypertensive agents ( Figure 1 ). 8, 9, 12, [16] [17] [18] The choice of pharmacological agent involves careful consideration of efficacy, benefit, co-pathology, interactions, adverse effects, cost-benefit, compliance and patient perception. While antihypertensive monotherapy has been the focus of clinical studies, combination therapy has often been required to reach target BP.
In both Syst-Eur and SHEP, inferior BP reduction in the diabetic cohorts compared with that in the non-diabetic cohorts, was still associated with superior reduction in morbidity and mortality in the diabetic patients. This raises two key points; that BP control is more difficult to achieve in the presence of diabetes mellitus, and that the benefits of BP lowering are greatest among such subjects, who are at high cardiovascular risk.
Combination therapy may potentially confer the advantage of improved efficacy through additive or synergistic effects. Rational add-on therapies to RAS inhibition include thiazide diuretics (especially in hypertensive patients exhibiting a low-renin state e.g. Afro-Caribbeans and black Americans), enhanced RAS blockade (ACE-I plus ARB), aldosterone antagonism (e.g. spironolactone) or CCBs (dihydropyridine or non-dihydropyridine). Addition of a β-blocker attenuates the activity of the RAS and is less logical. Adverse effects associated with centrally-acting agents reduce their usefulness in combination therapy. The α-antagonists have strengthened our therapeutic armoury for add-on therapy. There has been recent concern about the efficacy and safety of α-antagonists as first-line therapy in the light of findings from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). 19 However, the conclusions reached by the ALLHAT trialists with regard to α-antagonists are not shared by everyone and this interim report from ALLHAT does not consider or address the potential usefulness of α-antagonists as add-on therapy to improve BP control in high-risk 80 16 AASK, 17 HOT, 9 MDRD, 12 ABCD, 18 UKPDS. 8 patients. In this regard, all too few studies have addressed the preferred combination to use.
REVIEW
Fixed low-dose formulations may also improve compliance, reduce adverse effects when compared to high-dose monotherapy, reduce cost and help to achieve more rapid BP control.
Hypertension and diabetes
Hypertension and diabetes commonly co-exist and represent significant risk factors for the development of premature cardiovascular disease (cardiovascular mortality, congestive heart failure (CHF), IHD, cerebrovascular disease, peripheral vascular disease, nephropathy and retinopathy). Their co-existence has been reported to be associated with a relative risk of cardiovascular mortality of 2.25-3.66, a relative risk of cardiovascular events of 1.73-2.77 and a relative risk of total mortality of 1. 73-2.18. 20 Frequently implicated in this magnification of cardiovascular risk are dyslipidaemias, coagulation and platelet abnormalities, endothelial dysfunction,loss of compliance of capacitance arteries,autonomic dysfunction and increased oxidative stress. Aggressive BP lowering, regardless of drug class, is effective in reducing cardiovascular events in diabetic hypertensive patients. 20 Patients with hypertension commonly exhibit insulin resistance and are at elevated risk of developing Type 2 diabetes mellitus. Associated risk factors, including dyslipidaemias and elevated body mass index, confound this inter-relationship. Conversely, over 80% of Type 2 diabetics are hypertensive. In the presence of Type 1 diabetes, hypertension usually occurs subsequent to development of renal dysfunction. In Type 2 diabetes, hypertension is often present at diagnosis and usually precedes renal dysfunction.
Diabetic nephropathy, characterised by increasing BP, declining glomerular filtration rate (GFR) and development of proteinuria, develops in approximately 30-40% of patients with diabetes.Tight BP control is the single most effective intervention in delaying progression to end-stage renal disease (ESRD), as well as diminishing the cardiovascular risk associated with hypertension and diabetes ( Figure 2 ). 12, 14, [21] [22] [23] [24] [25] [26] [27] [28] There are very few cardiovascular endpoint studies comparing classes of antihypertensive agents in diabetes. The exception is the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 29 which showed that, despite equivalent BP control, losartan-based therapy was more effective than atenolol-based therapy at reducing cardiovascular morbidity and mortality and total mortality in people with Type 2 diabetes and ECG evidence of LVH. LIFE aside, most studies have used the surrogate markers of BP control, microalbuminuria, and proteinuria, which are known to be independent predictors of subsequent cardiovascular disease. Reduction in proteinuria in diabetes is associated with a slowed progression of renal disease.
Type 1 diabetes mellitus and proteinuria
The presence of persistent microalbuminuria is the first marker of impaired kidney function. Unless relevant therapeutic interventions take place, the disease process will progress, albumin excretion will increase and ESRD will finally ensue (with a median delay of eight years).The presence of clinical proteinuria (≥1 g/day) usually reflects overt nephropathy, pathologically represented by diabetic glomerulosclerosis. Antihypertensive therapy targeting tight BP control at an early stage in the natural history can prevent the progression of each stage of diabetic nephropathy and is associated with improved survival. 30, 31 There is also compelling evidence that ACE inhibition can complement the effects of BP control and further delay the progression of renal disease in Type 1 diabetes, especially in patients with proteinuria ≥1 g/day (see below).
Type 2 diabetes mellitus and proteinuria
In Type 2 diabetic patients, similar measures are effective in preventing and slowing the progression of diabetic nephropathy. Microalbuminuria may also be seen in these patients as a marker of generalised macrovascular disease and so is a less specific marker of incipient nephropathy than in Type 1 diabetics.Therefore, in Type 2 diabetics, microalbuminuria identifies a patient cohort with an increased risk not only of renal, but also of cardiovascular disease.The occurrence of macroalbuminuria in these patients points to already advanced glomerular damage. The UKPDS study 32 confirmed glycaemic control as being of benefit in preventing microvascular complications, and the Hypertension in Diabetes Study subgroup 33 identified the association between tight BP control and reduction in both macrovascular and microvascular events. Furthermore, irbesartan-based therapy and losartan-based therapy have been shown to complement BP control and further delay the progression of renal disease in patients with Type 2 diabetes and overt nephropathy. 16, 34, 35 
Renal disease and hypertension
In clinical practice, the two most important causes of ESRD are diabetes mellitus and hypertension. Once renal disease is present, the level of BP and proteinuria determine the rate of decline in renal function towards ESRD.The MDRD study showed that in proteinuric renal disease, a mean arterial pressure (MAP) of 92 mmHg slowed the progression of renal disease significantly compared with a MAP of 107 mmHg. 12 This has led to the tight BP guidelines recommended by advisory bodies (see Table 1 ), particularly if proteinuria of >1 g/day is present. The inverse linear relationship between systolic BP (SBP) and GFR in clinical studies is striking (see Figure 2 ). The LIFE study 29 collected data on microalbuminuria (urine albumin/creatinine ratio [UACR] >3.5 mg/mmol) and macroalbuminuria (UACR >35 mg/mmol). Among the cohort of 8,029 hypertensive patients with LVH in whom this data was available, 73% had a normal UACR, 23% microalbuminuria and 4% macroalbuminuria. Macroalbumin-uria was positively related to endpoints, independently of age, BP, diabetes, race, serum creatinine or smoking. 33 At the time of writing, data is not available on the treatment-related outcomes stratified according to the level of microalbuminuria.
The ongoing African-American Study of Kidney Disease (AASK) of hypertensive nephrosclerosis is using a 3x2 factorial design to address 'low' versus 'usual' BP targets, using three different antihypertensive agents; an ACE-I (ramipril), a dihydropyridine CCB (amlodipine) and a β-blocker (metoprolol). Interim analysis has led to the discontinuation of the amlodipine arm, on the basis of a significant (36%) difference in decline of GFR among patients with proteinuria at baseline (urinary protein: creatinine ratio of >0.22) over three years of follow-up, and a significant increase in secondary endpoints of fall in GFR to 50% or less of baseline, progression to renal replacement therapy and death, among these patients. 17 This difference was not present in patients with a urinary protein: creatinine ratio of <0.22 at randomisation.
There is very little clinical outcome data available on the use of CCBs in non-diabetic renal disease (see below).
The primacy of renin-angiotensin system blockade
Angiotensin-converting enzyme inhibitors in diabetes mellitus ACE-I have favourable metabolic, renal, cardiovascular and quality-of-life effects compared with other antihypertensive agents. In addition to lowering BP, they are thought to oppose the increased intraglomerular pressure that is mediated by Ang II through preferential dilation of the efferent arteriole. Currently, ACE-I are the recommended firstline agents in patients with Type 1 diabetes. Paradoxically, their use has not been sufficiently validated in Type 2 diabetic nephropathy. Two metaanalyses have confirmed the renoprotective effect of ACE-I in diabetic patients. 36, 37 Type 1 diabetes mellitus Studies have shown the use of ACE-I in Type 1 dia-betes mellitus can prevent the progression of microalbuminuria to overt proteinuria, 25, 38 reduce proteinuria in patients with overt diabetic nephropathy, 39 slow the deterioration of GFR, 25 delay progression to ESRD, 13 and lower BP. Whether these responses are dose-dependent remains uncertain. A non-significant trend towards a dose-dependent renoprotective effect of ramipril was observed in the ACE inhibitor Trial to Lower Albuminuria in Normotensive Insulin-dependent Subjects (ATLANTIS) 40 of normotensive microalbuminuric patients with Type 1 diabetes.
In the Type 1 diabetic patient without evidence of incipient nephropathy, the preventive potential of ACE inhibition upon development of albuminuria has been the subject of conflicting study results, 41, 42 and requires further investigation through long-term follow-up studies.
Type 2 diabetes mellitus
Only limited data exist on whether ACE-I demonstrate consistent risk reduction in patients with Type 2 diabetes mellitus and evidence of renal disease. Studies of normotensive Type 2 diabetics have provided evidence of the benefit of the ACE-I, enalapril, in preventing development of microalbuminuria, 43 and stabilisation of serum creatinine, urinary albumin excretion rate and BP compared with placebo in the presence of microalbuminuria. 44, 45 In hypertensive Type 2 diabetics, enalaprilbased therapy also diminished the rate of decline in GFR in patients with subclinical proteinuria, as well as the incidence of progression to clinical albuminuria, compared with antihypertensive regimens excluding ACE-I. 26 In the presence of overt nephropathy, the superiority of ACE-I based therapy has been demonstrated over a βblocker/diuretic combination in retarding decline in GFR and reducing proteinuria. 46 Substudies of major clinical trials addressing endpoints of macrovascular complications of Type 2 diabetes in the presence of hypertension have been underpowered to detect differences between treatment arms. The results of Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation (MICRO-HOPE), 47 demonstrating a reduction in the risk of development of overt diabetic nephropathy and relative reduction in the risk of myocardial infarction (MI), stroke, cardiovascular death and total mortality among Type 2 diabetics with at least one additional cardiovascular risk factor using treatment with ramipril compared with placebo, may reflect subtle differences in BP between the two groups of high-risk patients.
Comparisons between classes of antihypertensive agent were undertaken in the Hypertension in Diabetes substudy of UKPDS, which demonstrated that therapy based on captopril or atenolol was similarly effective at reducing microvascular and macrovascular complications, though this study was underpowered to detect any differences due to individual drug treatment. 48 The diabetes mellitus subgroup of the Captopril Prevention Project (CAPP), 49 which aimed to compare the REVIEW effects of ACE inhibition and conventional therapy on cardiovascular morbidity and mortality in patients with hypertension, was similarly underpowered to demonstrate significant differences beyond BP reduction between the two treatment groups, and there has been criticism of its study design, particularly the once-daily dosing of captopril with its potential confounding effect on 24hour BP control, which was not examined, and baseline discrepancies between the study groups, which may confound the results. Interestingly, an increased rate of development of diabetes mellitus among hypertensive patients was observed in the conventional treatment group. There was a similar lack of power to detect differences in endpoint in the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) 50 elderly diabetic cohort, which detected no differences beyond the effects of BP lowering between 'newer' treatments (CCBs or ACE-I) or 'conventional' treatment (thiazide diuretics and β-blockers).
Angiotensin II AT 1 -receptor blockers in diabetes mellitus
In contrast to cardiovascular endpoint studies with ACE-I, studies of ARBs have concentrated on Type 2 diabetes.
Type 1 diabetes mellitus
No head-to-head comparison between the effect of ACE-I and ARB therapy on cardiovascular endpoints in Type 1 diabetes mellitus has been performed. However, similar reductions in albuminuria have been demonstrated in patients with IDDM and overt nephropathy using losartan and enalapril in a two-month randomised, doubleblind, crossover trial. 51 Type 2 diabetes mellitus A comparison study of the ARB, losartan, and the ACE-I, enalapril, over a one-year period in hypertensive Type 2 diabetics with early nephropathy have shown similar reductions in albuminuria. 52 The renoprotective effect of ARBs in the presence of Type 2 diabetes, hypertension and microalbuminuria in delaying the development of diabetic nephropathy was demonstrated in IRMA 2 (Irbesartan in patients with Type 2 diabetes mellitus and MicroAlbuminuria). 34 This effect was dosedependent. A statistically significant increase in regression to normoalbuminuria against placebo was also observed. These differences were independent of the antihypertensive effect of the active compound.
In patients with Type 2 diabetes and overt nephropathy, the renoprotective action of ARBs was evident in two large scale trials. RENAAL (Reduction of Endpoints in NIDDM with the Ang II Antagonist Losartan Study) 35 demonstrated a 16% risk reduction in the primary composite endpoint of doubling of baseline serum creatinine concentration, ESRD or death from a cardiovascular cause, when comparing losartan with placebo. The Irbesartan Diabetic Nephropathy Trial (IDNT) 16 compared irbesartan, amlodipine and conventional therapy, and demonstrated superiority of irbesartan over amlodipine and conventional therapy in reducing the primary endpoint of doubling of baseline serum creatinine, ESRD or all-cause mortality, with similar BP reduction across all three cohorts.
The LIFE study 29 demonstrated a significant 25% reduction in new onset diabetes in losartantreated patients, compared with atenolol-treated patients, amongst a high cardiovascular risk group with hypertension and LVH on ECG. The subcohort of 1195 (13%) patients with Type 2 diabetes mellitus derived additional clinical benefit with losartan over atenolol, with a 24% relative risk reduction in the primary composite endpoint (death, MI or stroke), and a 39% reduction in total mortality. A 2 mmHg difference in systolic BP at the end of the study favoured the losartan group.
ACE-I and ARBs are now accepted as exerting cardioprotective and renoprotective effects independently of their BP-lowering actions, 53 and in the absence of contraindications, should be initial therapy for the hypertensive patient with diabetes, or the patient with hypertension and renal dysfunction. Multiple medications are usually required to lower BP. 20 In the absence of clinical endpoint studies, the ideal choice of second-line antihypertensive agent remains uncertain.
Calcium channel blocker therapy
CCBs are a heterogeneous class of effective, welltolerated vasodilatory antihypertensive drugs comprising the dihydropyridines (e.g. nifedipine, amlodipine), the phenylalkylamines (e.g. verapamil) and the benzthiazepines (e.g. diltiazem). Their antihypertensive benefit is well documented in the elderly, and in the presence of isolated systolic hypertension. 54 Other indications include the treatment of symptomatic coronary artery disease, pulmonary hypertension, supraventricular cardiac arrhythmias, prevention and treatment of cerebral vasospasm in subarachnoid haemorrhage and Raynaud's phenomenon.
The safety and benefit of CCBs as antihypertensive agents in diabetic patients was established in the diabetic cohorts of the HOT, 9 Syst-Eur, 10 Nordic Diltiazem study (NORDIL) 55 and International Nifedipine GITS Study Intervention as a Goal in Hypertension Treatment (INSIGHT) 56 trials. Concerns about possible adverse effects on fatal and non-fatal MI associated with the shortacting dihydropyridine CCBs were raised through a meta-analysis, 57 and centred upon comparative trials with ACE-I; Appropriate Blood pressure Control in Diabetes (ABCD) 18 and Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). 58 These concerns were based upon subgroup analyses of low numbers of events. Placebocontrolled studies have suggested that this observation was likely to be due to additional cardiovascular benefits attributable to ACE-I beyond the reduction in BP, rather than to an increased risk associated with dihydropyridine CCBs. Whilst there was a suggestion of reduced mortality with non-dihydropyridine CCBs in the meta-analysis, the available data was insufficient. The BP Lowering Treatment Trialists' Collaboration 59 suggest a beneficial effect of dihydropyridine CCBs in reducing the risk of stroke and other cardiovascular events by 30-40%, mainly among elderly patients with isolated systolic hypertension. A further notable effect of CCBs is their efficacy in reversal of LVH. 60 Beside their systemic effect on BP, the renal effects of CCBs are less clear.Their administration results in afferent arteriolar (preglomerular) vasodilatation and a natriuretic effect. Whilst this alone should not reduce intraglomerular pressure, nonpressor effects have been postulated to account for their beneficial effects on the renal microcirculation and excretory function. 61 In patients with proteinuria, studies have shown that the dihydropyridine CCBs do not lower proteinuria, despite a reduction in BP. Information on the effects of the non-dihydropyridine CCBs is limited to a small number of studies in patients with dia-betic renal disease, that suggest a greater antiproteinuric effect than that seen with dihydropyridine CCBs. However, as interesting as these observations are, the number of patients in these studies is small and it would be unsafe to conclude that such drugs are any more effective at renoprotection than conventional dihydropyridines. In this regard, it is surprising that these findings have been given such prominence in USA guidelines for renoprotection.
Type 1 diabetes mellitus
Dihydropyridine CCBs in particular demonstrate marked heterogeneity in their effect on albumin excretion ratio. This heterogeneous effect upon albumin excretion in hypertensive Type 1 diabetics may be related to variations in sodium intake. 62 This effect has also been observed in treatment with long-acting diltiazem preparations 63 and ACE-I. 64 In the normotensive Type 1 diabetic with microalbuminuria, two three-year studies have shown disparate results on the level of albumin excretion with nifedipine, compared with ACE inhibition and placebo. The Melbourne Diabetic Nephropathy Study Group demonstrated an increase in albumin excretion ratio which was similar to placebo after three years of therapy with nifedipine, compared with a reduction in albumin excretion ratio associated with the use of the ACE-I, perindopril. 65 The Italian Microalbuminuria Study Group in Type 1 diabetes suggested no significant difference in reduction in albumin excretion ratio after three years of therapy with nifedipine versus the ACE-I, lisinopril. 66 The numbers of patients in both studies were small. In the presence of hypertension and macroalbuminuria, a four-year follow-up study comparing nisoldipine with lisinopril has suggested a similar rate of decline in GFR between the two drugs, although ACE inhibition was associated with a reduction in albumin excretion ratio compared with an unchanged albumin excretion ratio with calcium channel blockade. 67
Type 2 diabetes mellitus
Comparative studies of CCBs with other agents in Type 2 diabetic renal disease are summarised in Table 2 . 27, 28, [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] It can be seen that dihydropyridine CCBs tend to have a neutral or adverse effect on proteinuria, whereas the non-dihydropyridine CCBs stabilise or reduce the rise in proteinuria, with the caveat that these studies are really too small to draw definitive clinical conclusions. 82 In a single small study, GFR and albumin excretion were comparable using cilazapril versus amlodipine. 73 This heterogeneous effect on proteinuria in patients with diabetic nephropathy has been evaluated by Smith et al. 83 in a comparative study of the antiproteinuric effects of the dihydropyridine CCB, nifedipine, against the non-dihydropyridine CCB, diltiazem. Potential mechanistic explanations for the observed difference include alteration in glomerular permeability, haemodynamic changes, intraglomerular haemodynamic effects, differential effects on matrix proteins or differential calcium channel distribution on the glomerular capillary wall.
Three major, randomised, controlled clinical studies have compared CCB therapy with RAS blockade in patients with Type 2 diabetes mellitus. IDNT 16 confirmed renoprotective superiority of the ARB irbesartan over amlodipine in the presence of proteinuria, despite similar BP reduction in treatment groups. The ABCD trial 18 provided a comparison of nitrendipine versus enalapril in hypertensive Type 2 diabetics with and without renal insufficiency. Whilst there was no statistical difference between the two agents in progression of diabetic nephropathy, as measured by creatinine clearance and urinary albumin excretion over five years of follow-up, an initial advantage associated with enalapril on urinary albumin excretion was observed in the first 36 months. The FACET study 58 demonstrated a significantly lower cardiovascular event rate in the ACE-I treatment group than in the CCB group, but lacked sta-tistical power to assess these secondary endpoints fully.The cohort of 108 patients receiving combination therapy with fosinopril and amlodipine showed a tendency to greater cardiovascular protection.
Combination of renin-angiotensin system blockade and calcium channel blocker therapy
Free combination therapy of RAS blockade plus CCBs has been widely used in clinical trials, though usually as add-on therapy to achieve target BPs. More recently, three fixed-dose combinations, comprising ACE-I plus CCB, have been licensed for use in the US; two dihydropyridine CCBs (benazepril/amlodipine, enalapril/felodipine) and a single non-dihydropyridine CCB (trandolapril/ verapamil SR), creating a further therapeutic option. In the UK, ramipril/felodipine and trandolapril/verapamil combinations are available.
CCBs act in a complementary manner to agents targeting the RAS and their antihypertensive effect should be beneficial, providing they do not negate any of the renoprotective effects of ACE inhibition/ARB therapy. Likely additional beneficial effects from addition of a CCB to RAS blockade include the potential for reduction in stroke, reduction of left ventricular mass, control of ventricular dysrhythmias, improving cardiac filling and contractility, decreasing atherogenesis, with additional possible antiproteinuric effects of nondihydropyridine CCBs. CCBs may, however, be less effective than ACE-I, diuretics or β-blockers in reducing the rate of MI or CHF. In the diabetic patient, the metabolic neutrality of a CCB with regard to glucose and lipid metabolism may be important. ACE inhibition also reduces the adverse effect of peripheral oedema associated with CCB therapy. 84 A review of early studies into the combination was published in 1988. 85 Substudy analyses from the Syst-Eur, 10 FACET 58 and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) 35 studies suggested no deleterious effect with the addition of CCBs to ACE-I or ARBs in patients with Type 2 diabetes. Notably, 77.9% (n=585) of the RENAAL patients randomised to the losartan arm received CCB therapy during the study. Other relatively small-scale studies into the combination have investigated the antihypertensive efficacy, time taken to control BP, the antiproteinuric effect in microalbuminuria or proteinuria, and the effect on progression of nondiabetic renal disease.
The antihypertensive efficacy of a fixed-dose combination of ACE-I + dihydropyridine CCB is at least additive compared to the individual drugs. It is superior to high-dose monotherapy with either agent and is well tolerated. [86] [87] [88] [89] [90] [91] In both fixed-and non-fixed-dose combinations, the two drugs exert a dose-dependent antihypertensive effect. 88, 92 Fixeddose combination therapy is equally as efficacious as ACE-I/thiazide or β-blocker/diuretic combinations. 93, 94 Greatest antihypertensive benefits are seen in elderly patients with isolated systolic hypertension. 95 The time taken to control BP in a diabetic population with hypertension is reduced and the renoprotective effects conferred by the ACE-I are not diminished by the addition of the CCB. 90 The combination of an ACE-I and a non-dihydropyridine CCB in patients with Type 2 diabetes, hypertension and proteinuria is more antiproteinuric at the same BP level than either drug taken alone [96] [97] [98] and associated with a reduction of rate of decline in GFR. 99 Similar results have been obtained in Type 1 diabetic patients with microalbuminuria. 100 In non-diabetic renal disease, the European Multicenter Study on Progression in Nondiabetic Renal Disease (NEPHROS) 101 compared 158 patients randomised to ramipril or felodipine monotherapy, or to combination therapy with the two drugs. Combination therapy was superior to felodipine monotherapy in retarding the progression of renal disease, but there was no significant difference compared with ramipril monotherapy.
Structural and functional changes have also been observed with an ACE-I/dihydropyridine CCB combination, independently of BP. They improve compliance of capacitance arteries to a significantly greater degree than ACE-I alone, 102 and exert beneficial effects on reduction of LVH. 103 The counter-controlled regulatory increase in sympathetic tone associated with the use of dihydropyridine CCBs is absent in fixed low-dose combination with an ACE-I. 104 The future for combination therapy with calcium channel blockers and angiotensin receptor blockers/angiotensin-converting enzyme inhibitors Testing each combination of therapies in a morbidity/mortality endpoint randomised clinical trial is not feasible. Current prospective randomised controlled hypertension trials of patients at elevated cardiovascular risk involving CCBs (ALLHAT, Valsartan Antihypertensive Long-term Use Evaluation [VALUE]) 105,106 focus on comparisons of monotherapy, with add-on therapy as required. AASK 17 will supply information on ACE-I or βblocker monotherapy in African-Americans with hypertensive nephrosclerosis, but the amlodipine arm has been withdrawn.The Anglo-Scandinavian Cardiovascular Outcomes Trial (ASCOT) 107 addresses first-and second-line antihypertensive agents added in a sequential manner to achieve target BP (<140/90; <130/80 in diabetics) in 19,342 hypertensive patients (22% of whom are diabetic) at elevated cardiovascular risk. Treatment arms are based on a dihydropyridine CCB (amlodipine), with ACE inhibition (perindopril) as add-on therapy, or the β-blocker (atenolol), with thiazide diuretic (bendroflumethazide) as add-on therapy. Providing the BPs in both treatment arms are well matched, the implications of this trial on antihypertensive combination therapy will be of great importance.
Summary
Effective reduction in BP improves survival and morbidity in patients with hypertension and diabetes or renal disease. In these patients, blockade of the RAS should be the primary therapeutic intervention in the absence of any contraindications. Combination therapy will almost always be necessary to control BP. Diuretic therapy is the logical add-on therapy following optimisation of the dose of ACE-I or ARB. The available evidence suggests that long-acting CCBs remain a logical, safe and very effective addition to further improve BP control. There is absolutely no evidence that adding a CCB to RAS blockade will in any way compromise the renoprotective actions of RAS blockade. On the contrary, the resulting fall in BP is of prime importance for renoprotection. There has also been controversy about potential differences between the CCBs, i.e. dihydropyridines versus non-dihydropyridines. There is no doubt that, in small trials, the latter appear to have a greater antiproteinuric effect than the former. However, these trials are too small to formulate healthcare policy. Moreover, when one considers that in patients with renal disease, RAS blockade will be the primary treatment, then the debate is really about whether there are real differences in patient outcomes when different classes of CCBs are added to ACE-I or ARBs. This seems most unlikely and is certainly unproven. On the contrary, in the RENAAL study based on losartan therapy, most patients received a dihydropyridine CCB as add-on therapy and this became the first study to show more effective prevention of ESRD, when compared with conventional BP-lowering therapy in patients with Type 2 diabetes and nephropathy. The available evidence suggests a simple approach to managing BP in diabetic patients; lower BP to recommended targets, or as low as the patient will tolerate, using as many drugs as it takes. RAS blockade, in combination with a thiazide diuretic, will generally be used as first-line therapy, followed by a CCB. Thereafter, α-antagonists, β-blockers or centrally-acting agents may be added. In patients with more advanced renal impairment, thiazides are likely to be ineffective and will need to be replaced by loop diuretics, often at high doses. The end result is more important than the means and we often need all available therapies, in combination, to achieve it.
